Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - ADVENTRX Pharmaceuticals, Inc. (ANX-NYSE Amex) |
|
|
“ADVENTRX stands out among its small cap peers because we expect to submit an NDA, the final regulatory hurdle to drug approval, this year. There is only a limited amount of work remaining before we submit that NDA, and we have both the financial and human capital to get there.” - Brian M. Culley, M.A., M.B.A. (ANX) (Interview published June 18, 2010) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
ADVENTRX to Present at the Wall Street
Analyst Forum 21st Annual Institutional Investor Conference on
November 11
SAN DIEGO, Nov. 4, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on Thursday, November 11, 2010 at 12:50 p.m. Eastern time, at The University Club in New York City. Interested parties can access a live audio webcast and slide presentation on the Company's web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com. SOURCE ADVENTRX Pharmaceuticals, Inc.
|
|
